Silke Gillessen

Active 1992–2025

163
Papers
30,662
Citations
79
h-index
155
i10-index

Citations

Citations per year for Silke Gillessen1993: 1 citations1994: 5 citations1995: 6 citations1996: 13 citations1997: 11 citations1998: 20 citations1999: 18 citations2000: 16 citations2001: 17 citations2002: 23 citations2003: 42 citations2004: 65 citations2005: 66 citations2006: 54 citations2007: 37 citations2008: 63 citations2009: 68 citations2010: 66 citations2011: 55 citations2012: 58 citations2013: 59 citations2014: 63 citations2015: 54 citations2016: 67 citations2017: 107 citations2018: 134 citations2019: 569 citations2020: 841 citations2021: 1,044 citations2022: 1,129 citations2023: 935 citations2024: 1,774 citations2025: 997 citations2026: 25 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,389 citing papers, 17.3% of this breakdownChina: 1,156 citing papers, 8.4% of this breakdownUnited Kingdom: 1,018 citing papers, 7.4% of this breakdownItaly: 961 citing papers, 7% of this breakdownGermany: 925 citing papers, 6.7% of this breakdownFrance: 678 citing papers, 4.9% of this breakdownCanada: 621 citing papers, 4.5% of this breakdownSwitzerland: 534 citing papers, 3.9% of this breakdownNetherlands: 529 citing papers, 3.8% of this breakdownAustralia: 463 citing papers, 3.4% of this breakdownSpain: 463 citing papers, 3.3% of this breakdownJapan: 366 citing papers, 2.6% of this breakdown
0%17.3%Other 26.8%

Fields

  • Medicine71.2%
  • Biochemistry, Genetics and Molecular Biology13.3%
  • Immunology and Microbiology8.8%
  • Chemistry2%
  • Neuroscience1%
  • Computer Science0.8%
  • Other2.9%

Topics

  • Prostate Cancer Treatment and Research14.7%
  • Prostate Cancer Diagnosis and Treatment11.3%
  • Radiopharmaceutical Chemistry and Applications3.4%
  • Immunotherapy and Immune Responses2.9%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Cancer, Lipids, and Metabolism2.5%
  • Other62.6%

Coauthors

All papers

Open in search
  1. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 2,814

  2. Prostate cancer

    Authors: , , , , , , , , - Nature Reviews Disease Primers 2021 cited by 1,109

  3. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Derya Tilki - European Urology 2024 cited by 1,087

  4. The Lancet Commission on prostate cancer: planning for the surge in cases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anwar R. Padhani, Charles Parker, Hannah Rush, Mark Sculpher, Howard R. Soule, Matthew R. Sydes, Derya Tilki, Nina Tunariu, Paul Villanti, Liping Xie - The Lancet 2024 cited by 643

  5. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , - Annals of Oncology 2020 cited by 953

  6. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes - New England Journal of Medicine 2017 cited by 1,772

  7. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , - Annals of Oncology 2021 cited by 525

  8. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , - Annals of Oncology 2019 cited by 1,159

  9. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 1,126

  10. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes - The Lancet 2018 cited by 1,262

  11. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marco Bolis, Fabio Grassi, Antonio Esposito, Matteo Bellone, Alberto Briganti, María Rescigno, Jean‐Philippe Theurillat, Christian Jobin, Silke Gillessen, Johann S. de Bono, Andrea Alimonti - Science 2021 cited by 322

  12. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 cited by 242

  13. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 517

  14. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip Cornford - European Urology 2024 cited by 313

  15. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  16. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey and 73 more - The Lancet 2021 cited by 367

  17. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , , - Annals of Oncology 2024 cited by 300

  18. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

    Authors: , , , , , , , , , , , , - Annals of Oncology 2024 cited by 159

  19. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joanna Gale, Stephanie Gibbs, Anna Lydon, Ashok Nikapota, Aurelius Omlin, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Sarah Rudman, Narayanan Srihari, Matthew Simms, Jacob Tanguay, Shaun Tolan, John Wagstaff, Jan Wallace, J. Wylie, Anjali Zarkar, Matthew R. Sydes, Mahesh Parmar, Nicholas D. James - Annals of Oncology 2019 cited by 398

  20. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 110

  21. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan C. Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise Brown, Mahesh Parmar, Nicholas D. James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, D. Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, M. Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan B. McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry M. Taylor, John D. Graham and 80 more - The Lancet Oncology 2023 cited by 102

  22. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  23. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

    Authors: , - Annals of Oncology 2023 cited by 117

  24. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology Focus 2019 cited by 242